优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点

智通财经06-01

智通财经APP获悉，优时比(UCB)和百健(BIIB.US)周一宣布，双方联合开发的在研药物dapirolizumab pegol(DZP)在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。资料显示，Dapirolizumabpegol是一种新型、在研、靶向CD40配体(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640593626?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-01 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640593626","market":"fut","top_or_hot":-1,"title":"优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，优时比(UCB)和百健(BIIB.US)周一宣布，双方联合开发的在研药物dapirolizumab pegol(DZP)在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。资料显示，Dapirolizumabpegol是一种新型、在研、靶向CD40配体(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448413.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n优时比与百健(BIIB.US)狼疮新药dapirolizumab pegol三期临床试验达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-01 14:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1448413.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，优时比(UCB)和百健(BIIB.US)周一宣布，双方联合开发的在研药物dapirolizumab pegol(DZP)在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。资料显示，Dapirolizumabpegol是一种新型、在研、靶向CD40配体(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448413.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1448413.html","article_id":"2640593626","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640593626","pubTimestamp":1780297012,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，优时比和百健周一宣布，双方联合开发的在研药物dapirolizumab pegol在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。BICLA 是一项复合疗效终点指标，用于评估患者所有受累器官系统的疾病活动度是否出现具有临床意义的改善，同时其他狼疮相关病症未发生恶化。安全性方面，该药严重不良事件发生率为 10%，低于安慰剂组的 14.8%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BIIB":"渤健公司","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"UCB and Biogen (BIIB.US) Phase III clinical trial of new lupus drug dapirolizumab pegol reaches primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"智通财经APP获悉，优时比(UCB)和百健(BIIB.US)周一宣布，双方联合开发的在研药物dapirolizumab pegol(DZP)在治疗系统性红斑狼疮的三期临床试验中达到了主要终点。试验数据显示，用药组患者在第 48 周实现 BICLA 应答的比例达 50%，安慰剂组为 35%，组间差异具有统计学意义。资料显示，Dapirolizumabpegol是一种新型、在研、靶向CD40配体(CD40L，也被称为CD154)并与聚乙二醇(PEG)偶联的抗体片段(Fab)。本次试验针对中重度活动性系统性红斑狼疮(SLE)患者开展。BICLA 是一项复合疗效终点指标，用于评估患者所有受累器官系统的疾病活动度是否出现具有临床意义的改善，同时其他狼疮相关病症未发生恶化。BICLA 应答率越高，代表治疗效果越理想，也意味着患者可获得临床获益。由于首个关键次要终点(第 24 周 BICLA 应答)未达标，后续各项结果未进行多重性校正。整体来看，在多项评估指标上，DZP联合标准疗法(SOC) 均展现出积极疗效，包括重度 BILAG 病情复发、SRI-4、SLEDAI-2K、皮肤和关节相关的指标等。安全性方面，该药严重不良事件发生率为 10%，低于安慰剂组的 14.8%。目前正在招募患者参与验证性三期“PHOENYCS FLY”试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640593626","isCrawlerRequest":true}